COPD Drug Delivery Devices Market Recent News Size, Analysis and Forecast up to 2027

R&D and Product Innovation to Increase Adoption of COPD Drug Delivery Devices

The chronic obstructive pulmonary disease (COPD) drug delivery devices have garnered significant popularity in the past few decades, owing to consistent advancements in technology and development of innovative products. Inhaled medication has emerged as one of the most reliable and effective treatments for a broad range of respiratory diseases such as COPD and asthma. Within the COPD drug delivery devices market, focus on product innovation has gained significant momentum in the past 60 years - beginning from the advent of pressurized metered-dose inhalers. At present, although more than 230 devices and drug formulations are available, disease control continues to remain a major challenge.

Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74897

Stakeholders operating in the current COPD drug delivery devices market are expected to focus on the development of innovative inhalers to improve the overall effectiveness of the inhaled medication therapy. Some of the innovations that are likely to take place within the COPD drug delivery devices market are expected to focus on digital technologies linked with inhalers, chemistry and formulations, and design and device engineering. Moreover, research and development activities are being undertaken to improve targeted drug delivery to the lungs. Furthermore, significant rise in the number of patients suffering from chronic obstructive pulmonary diseases worldwide coupled with a surge in demand for easy-to-operate devices is expected to drive the COPD drug delivery devices market to a value of ~US$ 11 Bn by 2027.

Request the Coronavirus Impact Analysis on this Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74897

Buy _ Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=74897&ltype=S

COPD Drug Delivery Devices Entering a Digital Era

In the current COPD drug delivery devices market landscape, digital drug delivery devices are garnering significant popularity. Trends suggest a gradual shift toward improved digital inhalation devices primarily used to treat patients suffering from respiratory diseases, including asthma and COPD. In recent times, focus on the development of novel drug delivery devices and systems has gained significant momentum in the pharmaceutical sector. In their bid to improve patient outcomes, stakeholders operating in the current market space are increasingly focusing on product development by adopting a patient-centric model.

Key players operating in the COPD drug delivery devices market are enhancing the designs of conventional drug delivery devices to improve patient outcomes. In terms of type, the digital devices segment is expected to grow at a CAGR of ~5% during the forecast period (2019-2027), a higher CAGR growth than the manual devices segment, which is poised to grow at a CAGR of ~4% during the forecast period. Increase in the adoption of digital COPD drug delivery devices is expected to address the problems that conventional drug delivery techniques were incompetent in solving.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies Launch New Products to Stay Competitive in Global Market

Drug development pertaining to asthma has predominantly focused on new molecules in established classes, formulation of new devices, and a range of combination treatments. However, obtaining the approval of the FDA for these new COPD drug delivery devices is likely to remain a key for participants in the COPD drug delivery devices market landscape. In their efforts to establish a strong foothold in the market, several companies are launching new products with innovative designs and improved digital capabilities.

For instance, Lonza launched Capsugel ® Zephyr ™ - a new addition to the dry-powder inhalation capsule portfolio of the company. The company revealed that the launch of the new product was primarily aimed at fulfilling the growing demand for customized treatments for efficient COPD drug delivery.

While some stakeholders are adopting the strategy of product launches, others are actively engaged in seeking approval from the FDA. For instance, in December 2018, Teva announced that the FDA had approval its ProAir Digihaler COPD drug delivery device. The new device makes use of advanced sensors that can be connected to a mobile App, and is specifically developed for individuals suffering from COPD and asthma. The approval of this product is expected to provide an impetus for the adoption of digital technologies to develop cutting-edge COPD drug delivery devices. The COPD drug delivery devices market is a consolidated market with leading players, including Boehringer Ingelheim, GlaxoSmithKline plc, and AstraZeneca accounting for a collective market share of ~82% in 2018.

Expanding operations in future? To get the perfect launch ask for a custom report